- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Genelux GAAP EPS of -$0.20 | 1 | Seeking Alpha | ||
| 07.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 19.03. | GENELUX Corp - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 19.03. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 19.03. | Genelux GAAP EPS of -$0.86 misses by $0.01 | 2 | Seeking Alpha | ||
| 19.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | 700 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses... ► Artikel lesen | |
| 19.03. | GENELUX Corp - 10-K, Annual Report | 2 | SEC Filings | ||
| 02.02. | GENELUX Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 12.01. | Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners | 4 | GlobeNewswire (USA) | ||
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; Genelux's Olvi-Vec Shows Promise; Monte Rosa Therapeutics' MRT-8102 Advances | 744 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 08.01. | Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock | 5 | GlobeNewswire (USA) | ||
| 07.01. | Genelux kündigt öffentliches Angebot von Stammaktien an | 4 | Investing.com Deutsch | ||
| 07.01. | Genelux announces proposed public offering | 1 | Seeking Alpha | ||
| 07.01. | Genelux Corporation Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 05.01. | Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data | 4 | Investing.com | ||
| 05.01. | Genelux-Aktie: Positive Studiendaten stützen Kaufempfehlung von H.C. Wainwright | 3 | Investing.com Deutsch | ||
| 02.01. | GENELUX Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 02.01. | Genelux Corp Appoints Jason Litten CMO | 3 | RTTNews | ||
| 02.01. | Genelux appoints Jason Litten as chief medical officer | 1 | Investing.com | ||
| 02.01. | Genelux beruft Jason Litten zum neuen Chief Medical Officer | 3 | Investing.com Deutsch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INFLARX | 1,391 | -0,57 % | Was Insider bei InflaRx NV heute bereits wissen: Das Signal das die meisten Anleger noch nicht kennen - Was das für Ihr Depot bedeutet! | ||
| REDHILL BIOPHARMA | 0,880 | 0,00 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| IMMUNIC | 10,045 | -1,23 % | EQS-News: Immunic AG: Immunic to Participate in Investor, Industry and Scientific Conferences in June | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor, Industry and Scientific Conferences in June
10.06.2026 / 12:30 CET/CEST
The issuer is... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 0,970 | +2,11 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| CYBIN | 3,410 | +1,49 % | Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs | Dr. Kramer's 25 years' of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and TORONTO... ► Artikel lesen | |
| KYNTRA BIO | 5,750 | -3,36 % | KYNTRA BIO, INC. - 8-K, Current Report | ||
| OUTLOOK THERAPEUTICS | 0,782 | +1,56 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) | ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg... ► Artikel lesen | |
| KARYOPHARM | 7,850 | -0,63 % | Cantor Fitzgerald reiterates Overweight on Karyopharm stock | ||
| BIOLINERX | 2,520 | -1,56 % | BioLineRx Ltd.: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update | - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -
- Announced new GLIX1 data demonstrating potent anti-tumor... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,682 | 0,00 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
Elfabrio commercial execution continues following European Commission approval of the 2 mg/kg... ► Artikel lesen | |
| EDESA BIOTECH | 4,300 | -5,29 % | Edesa Biotech, Inc.: Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury | Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis... ► Artikel lesen | |
| CAN-FITE BIOPHARMA | 2,890 | 0,00 % | Can-Fite BioPharma Ltd.: Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months | Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,640 | 0,00 % | Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher | ||
| BRIACELL THERAPEUTICS | 2,760 | -0,72 % | BriaCell Therapeutics Corp. - 10-Q, Quarterly Report | ||
| CINGULATE | 4,890 | 0,00 % | Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 | Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts... ► Artikel lesen |
Das Unternehmen GENELUX CORPORATION kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.